Logo

Regeneron's REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

Share this

Regeneron's REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

Shots:

  • Regeneron reports first data of seamless P-I/II/III study assessing REGN-COV2 that demonstrated a reduction in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. It also reduces the medical visit
  • The descriptive analysis assesses REGN-COV2 (8gm/ 2.4gm) vs PBO in the first 275 patients enrolled in the trial in a ratio (1:1:1).  The trial suggested that REGN-COV2 could help patients whose own immune system is not strong enough to combat the virus
  • In seronegative patients- the median time to symptom relief is (8/6days vs 13days)- rapid reduction in viral load. Regeneron believes its dual-antibody formula will limit the ability of the virus to escape detection and attack

­ Ref: Regeneron | Image: Asia News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions